We are proud to announce the official launch of the Egypt Pharmacometrics Chapter, a dedicated community of scientists, clinicians, and educators committed to advancing clinical pharmacology and model-informed drug development (MIDD) across Egypt, the Middle East, and Africa. Egypt now formally joins a growing continental network of national pharmacometrics chapters, united in the conviction that quantitative science can meaningfully transform the way medicines are developed, evaluated, and personalised for patients.
The Egypt Pharmacometrics Chapter is part of the Pharmacometrics Africa network. We bring together researchers, clinical pharmacologists, pharmaceutical scientists, and educators from across Egypt who share a common ambition: to build a rigorous, inclusive, and impact-driven pharmacometrics community that can hold its own on the world stage. Our work is grounded in science and driven by a sense of regional responsibility, the belief that Egypt, sitting at the crossroads of the Middle East and Africa, is uniquely positioned to lead.
Why Pharmacometrics Matters for Egypt, the Region, and the World
Drug development has never been more quantitative. Across the globe, regulators, industry, and clinical scientists are turning to model-informed approaches such as pharmacometrics, population pharmacokinetic/pharmacodynamic modelling, physiologically based pharmacokinetic modelling, and systems pharmacology to make smarter, faster, and more ethical decisions about medicines. This shift is not a trend; it is a transformation, and it carries profound implications for countries like Egypt and the broader Middle East and Africa.
MIDD represents a framework that integrates mathematical and computational models throughout the entire drug development lifecycle from preclinical candidate selection and dose-finding to clinical trial design and regulatory submission. As a recent review highlighted that MIDD has the potential to significantly enhance the efficiency and success rates of drug development tailored to regional health priorities, by leveraging local data and advanced computational techniques (Alasamri et al). For the MENA region specifically, the review underscores the critical need for MENA countries to embrace MIDD by investing in workforce training, aligning regulatory frameworks, and fostering collaborative research initiatives. Egypt sits at the centre of this call to action.
The significance of this moment extends beyond science. In June 2023, Egypt became a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the first country in Africa to do so. This milestone signals Egypt’s formal entry into the global arena of pharmaceutical standards-setting, and it places the country in a unique position: not merely a recipient of international guidelines, but an active participant in shaping them. The Egyptian Drug Authority (EDA) has participated in the ICH M15 working group, contributing to the development of a harmonized framework for evaluating MIDD evidence and associated regulatory practices. Pharmacometrics is deeply embedded in ICH technical work, making quantitative expertise not just useful, but strategically essential for Egypt’s expanding regulatory role.
The relevance of pharmacometrics to low- and middle-income countries (LMICs) is also particular and urgent. Populations across Africa and the Middle East carry distinct disease burdens, genetic profiles, and healthcare infrastructure constraints that are systematically underrepresented in the global drug development literature. Without local pharmacometric capacity, medicines are dosed and evaluated based on data from populations that may not reflect regional biology or context. Building this capacity means that Egyptian and African scientists can generate the evidence base that regional patients deserve, informing dose optimisation for endemic infectious diseases, improving oncology outcomes in under-resourced settings, and supporting the rational adoption of generic and biosimilar medicines.
Critically, pharmacometrics is feasible to implement as a standard workflow, even in resource-limited academic and clinical environments. The foundational tools (population PK modelling, nonlinear mixed-effects modelling, simulation frameworks) are available through open-source platforms. Training pathways now exist through initiatives like the PMX Africa Applied Pharmacometrics Training (APT) Fellowship and through integration with existing clinical pharmacy and research programmes. What is required is not infrastructure that rivals global industry; it is trained scientists who understand the methodology, institutions that value the approach, and networks that connect practitioners across disciplines and borders.
The Egypt Pharmacometrics Chapter’s Role
Addressing this opportunity requires coordinated, ground-level action. The Egypt PMX Chapter operates through three reinforcing commitments: growing the people, through training programmes, applied workshops, and fellowship support; growing the science, by connecting researchers across institutions and linking Egypt to the wider PMX Africa network for collaborative, cross-disciplinary work; and growing the ecosystem, by fostering knowledge exchange and embedding pharmacometric thinking into national and regional regulatory frameworks.
Trained scientists produce stronger research, stronger research informs better regulation, and better regulation creates the conditions for science to flourish. This is how the chapter translates the promise of pharmacometrics into lasting impact for Egypt, the region, and the patients they serve.
Join Us
This launch is a beginning. We warmly invite pharmacometricians, clinical pharmacologists, researchers, academics, industry professionals, regulators, and sponsors to connect with us. Whether to collaborate, contribute expertise, explore training opportunities, or follow what we are building. The frontier of pharmacometrics in Egypt and Africa is wide open, and we move it together.
Alasmari MS, Albusaysi S, Elhefnawy M, Ali AM, Altigani K, Almoslem M, Alharbi M, Alghamdi J, Alsultan A. Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region. Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27. PMID: 39697476; PMCID: PMC11653594.